Results 81 to 90 of about 167,688 (127)

Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease [PDF]

, 2015
WOS: 000363832600010PubMed: 26338166Fabry disease, an X-linked lysosomal storage disorder, is caused by alpha-galactosidase A deficiency and leads to accumulation of glycospinhgolipids in most tissues, with life-theratening consequences in the kidney ...
Bahçebaşı, Zerrin Bicik, Taşçı, Elif Şenocak   +1 more
core  

Clearing of GB3 From Endothelial Vessels of Ocular Conjunctiva in Fabry Patients Treated with Agalsidase-Alfa

, 2006
Fabry\u27s disease is an X-linked inborn metabolic error caused by a deficiency of lysosomal ?- galactosidase A. Globotriaosylceramide (Gb3) accumulates in lysosomes of various cells.
R. Ebner; P. Rozenfeld; O. Croxatto; C. Fossati
core  

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease : A Fabry Outcome Survey analysis

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease.
Beck, Michael, Kampmann, Christoph, Giugliani, Roberto, Ramaswami, Uma, Hughes, Derralynn, Mehta, Atul, Universitat Autònoma de Barcelona, Larroque, Sylvain, Pintos-Morellell, Guillem, Wijatyk, Anna, West, Michael   +10 more
core  

Adequate hemodialysis does not compromise the cardioprotective effect of agalsidase alfa on patients with Fabry disease: a case report. [PDF]

J Med Case Rep
Wei X, Jiang S, Zhuo L, Jiang H, Li W.
europepmc   +1 more source

Long-term outcomes with agalsidase alfa enzyme replacement therapy : Analysis using deconstructed composite events

Altres ajuts: This work was supported by Shire International GmbH.This is a retrospective analysis of Fabry Outcome Survey data from children/adults (n = 677) receiving agalsidase alfa enzyme replacement therapy for a median of 3 years, examining ...
West, Michael L., Beck, Michael, Kampmann, Christoph, Giugliani, Roberto, Ramaswami, Uma, Hughes, Derralynn, Universitat Autònoma de Barcelona, Pintos-Morell, Guillem   +7 more
core  

Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report. [PDF]

North Clin Istanb
Cakmak ME.
europepmc   +1 more source

Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa. [PDF]

JIMD Rep, 2015
Goker-Alpan O, Nedd K, Shankar SP, Lien YH, Weinreb N, Wijatyk A, Chang P, Martin R.   +7 more
europepmc   +1 more source

Fabry cardiomyopathy presenting as hypertrophic phenotype with left ventricular outflow tract obstruction: a case series. [PDF]

Front Cardiovasc Med
Hosyanto FF, Li Y, Luo S, Huang B.
europepmc   +1 more source

Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment. [PDF]

Orphanet J Rare Dis, 2016
Kampmann C, Perrin A, Beck M.
europepmc   +1 more source

Impaired motor unit profile in Fabry disease: A quantitative electrophysiological study. [PDF]

Clin Neurophysiol Pract
Gunduz A, Akkan Suzan A, Dinçer MT, Özcan ŞG, Seyahi N.   +4 more
europepmc   +1 more source